Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity.
about
Roles of Erythroid Differentiation Regulator 1 (Erdr1) on Inflammatory Skin DiseasesBcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90.Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells.Bcl-xL Genetic Modification Enhanced the Therapeutic Efficacy of Mesenchymal Stem Cell Transplantation in the Treatment of Heart Infarction.Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth.Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.Induction of apoptosis in human cancer cells by candidaspongiolide, a novel sponge polyketide.Chemosensitization of prostate cancer by modulating Bcl-2 family proteins.Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule.bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity.Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatmentSensitization of SiHa cell to gemcitabine by CD40 activation and its overexpression in cervical carcinoma.Effective treatment of leukemic cell lines with wt1 siRNA.Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells.BCL-XL overexpression promotes tumor progression-associated properties.miR-211 and MITF modulation by Bcl-2 protein in melanoma cells.
P2860
Q28074548-181B532B-6D4E-4535-903B-434F618D0367Q33644391-BD913523-E3E3-4FFD-B14D-B4D3C49D0406Q33822119-A00A3234-C2A9-4CF0-9AE5-3466C024EB38Q35092701-73D8A0E6-C735-43F0-B33F-D43E18C0C395Q35621000-18A9E1AE-9B8E-4526-869F-9079153EFB31Q36670905-A46CCD57-0C0C-4ABF-B557-D45519102D4AQ37124747-58867264-F6D6-43AA-A8D7-54914096F110Q37288889-15E3EB17-6DAF-444F-A623-40C7A61A7AD7Q37713757-80678A68-0A8F-4DE0-892D-A7CAED2BE7CAQ37799747-AD18EFAA-5808-433C-8A06-E935F05DC34EQ38347131-622D1A48-D5F8-4600-901E-E98A7F8CCBDAQ39661214-B77A9D3E-BC66-4CDE-9E3A-9EA22A17662CQ39704018-F07BB7C0-0A7B-4786-AB47-35F8265B2E9CQ40095623-20D9D795-C0EE-43DE-AA8A-C842848B07A8Q40403536-C25747B9-BCB5-4D75-BBC1-503C338BD4B3Q48122093-A8892D06-5067-41E1-9A2B-D8CB488B4FF9Q53266571-F545C38A-E547-47FB-AE28-EFD01D3C21D8
P2860
Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Treatment of melanoma cells wi ...... duces antiangiogenic activity.
@en
type
label
Treatment of melanoma cells wi ...... duces antiangiogenic activity.
@en
prefLabel
Treatment of melanoma cells wi ...... duces antiangiogenic activity.
@en
P2093
P2860
P356
P1433
P1476
Treatment of melanoma cells wi ...... duces antiangiogenic activity.
@en
P2093
Gabriella Zupi
Marco Scarsella
Uwe Zangemeister-Wittke
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206999
P407
P577
2003-11-01T00:00:00Z
P5875
P6179
1002897543